Hepatocellular Carcinoma – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Hepatocellular Carcinoma – Pipeline Review, H1 2018’, provides an overview of the Hepatocellular Carcinoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hepatocellular Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hepatocellular Carcinoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Hepatocellular Carcinoma

– The report reviews pipeline therapeutics for Hepatocellular Carcinoma by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Hepatocellular Carcinoma therapeutics and enlists all their major and minor projects

– The report assesses Hepatocellular Carcinoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Hepatocellular Carcinoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Hepatocellular Carcinoma

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Hepatocellular Carcinoma pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Abivax SA

ACEA Biosciences Inc

Adaptimmune Therapeutics Plc

Advenchen Laboratories LLC

Alnylam Pharmaceuticals Inc

American Gene Technologies International Inc

Amgen Inc

AndroScience Corp

ArQule Inc

Array BioPharma Inc

Aslan Pharmaceuticals Pte Ltd

AstraZeneca Plc

AVEO Pharmaceuticals Inc

Bavarian Nordic A/S

Bayer AG

BeiGene Ltd

Bio-Cancer Treatment International Ltd

Biomics Biotechnologies Co Ltd

Bioneer Corp

Blueprint Medicines Corp

Boehringer Ingelheim GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Co

Can-Fite BioPharma Ltd

CARsgen Therapeutics Ltd

CASI Pharmaceuticals Inc

CBT Pharmaceuticals Inc

CCRP Therapeutics GmbH

Celgene Corp

Cellular Biomedicine Group Inc

Celsion Corp

China Medical System Holdings Ltd

Chipscreen Biosciences Ltd

Chugai Pharmaceutical Co Ltd

Conatus Pharmaceuticals Inc

Curevac AG

Delcath Systems Inc

Double Bond Pharmaceutical International AB

eFFECTOR Therapeutics Inc

Eiger BioPharmaceuticals Inc

Eisai Co Ltd

Eli Lilly and Co

Epeius Biotechnologies Corp

Epizyme Inc

Eureka Therapeutics Inc

Exelixis Inc

F. Hoffmann-La Roche Ltd

Faron Pharmaceuticals Oy

Galaxy Biotech LLC

GC Pharma

Genelux Corp

Genentech Inc

Genoscience Pharma

Genosco Inc

Gilead Sciences Inc

GlaxoSmithKline Plc

Golden Biotechnology Corp

H3 Biomedicine Inc

Hanmi Pharmaceuticals Co Ltd

Horizon Pharma Plc

Immatics Biotechnologies GmbH

Immunicum AB

Immunitor Inc

Immunomedics Inc

Immunovative Therapies Ltd

In-Cell-Art SAS

Incyte Corp

Inovio Pharmaceuticals Inc

Inspyr Therapeutics Inc

InteRNA Technologies BV

Jiangsu Hengrui Medicine Co Ltd

Johnson & Johnson

KAHR medical Ltd

Karcinolys SAS

Kite Pharma Inc

Komipharm International Co Ltd

Kowa Co Ltd

Kura Oncology Inc

Leap Therapeutics Inc

Lixte Biotechnology Holdings Inc

MaxCyte Inc

MedImmune LLC

Medivir AB

MELEMA Pharma GmbH

Merck & Co Inc

Merck KGaA

Merrimack Pharmaceuticals Inc

Midatech Pharma Plc

Millennium Pharmaceuticals Inc

Mina Therapeutics Ltd

Molecular Templates Inc

MTG Biotherapeutics Inc

MultiCell Technologies Inc

NeuroVive Pharmaceutical AB

Nkarta Inc

NormOxys Inc

Novartis AG

NovaTarg Therapeutics Inc

Nymox Pharmaceutical Corp

Omeros Corp

Oncolys BioPharma Inc

Oncolytics Biotech Inc

Oneness Biotech Co Ltd

Ono Pharmaceutical Co Ltd

Oxford BioTherapeutics Ltd

PepVax Inc

Pfizer Inc

Pharma Mar SA

PharmAbcine Inc

PharmaEssentia Corp

Phosplatin Therapeutics LLC

Provecs Medical GmbH

Provectus Biopharmaceuticals Inc

Q BioMed Inc

RedHill Biopharma Ltd

Regulus Therapeutics Inc

Rexahn Pharmaceuticals Inc

Samumed LLC

Saronic Biotechnology Inc

Sensei Biotherapeutics Inc

Shanghai Henlius Biotech Co Ltd

Shenogen Pharma Group Ltd

Sillajen Biotherapeutics

Simcere Pharmaceutical Group

Spring Bank Pharmaceuticals Inc

Sun Pharma Advanced Research Company Ltd

Takeda Pharmaceutical Co Ltd

TC BioPharm Ltd

Tessa Therapeutics Pte Ltd

Therapure Biopharma Inc

Tiziana Life Sciences Plc

TRACON Pharmaceuticals Inc

Trovagene Inc

Tumorend LLC

Twoxar Inc

Tyrogenex Inc

VasGene Therapeutics Inc

Verlyx Pharma Inc

VG Life Sciences Inc

Vicus Therapeutics LLC

Xencor Inc

Xspray Pharma AB

Yooyoung Pharm Co Ltd

Zhejiang Conba Pharmaceutical Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 9

Hepatocellular Carcinoma Overview 10

Hepatocellular Carcinoma Therapeutics Development 11

Hepatocellular Carcinoma Therapeutics Assessment 45

Hepatocellular Carcinoma Companies Involved in Therapeutics Development 67

Hepatocellular Carcinoma Drug Profiles 132

Hepatocellular Carcinoma Dormant Projects 1218

Hepatocellular Carcinoma Discontinued Products 1227

Hepatocellular Carcinoma Product Development Milestones 1230

Appendix 1244

List of Tables

List of Tables

Number of Products under Development for Hepatocellular Carcinoma, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Hepatocellular Carcinoma Pipeline by AbbVie Inc, H1 2018

Hepatocellular Carcinoma Pipeline by Abivax SA, H1 2018

Hepatocellular Carcinoma Pipeline by ACEA Biosciences Inc, H1 2018

Hepatocellular Carcinoma Pipeline by Adaptimmune Therapeutics Plc, H1 2018

Hepatocellular Carcinoma Pipeline by Advenchen Laboratories LLC, H1 2018

Hepatocellular Carcinoma Pipeline by Alnylam Pharmaceuticals Inc, H1 2018

Hepatocellular Carcinoma Pipeline by American Gene Technologies International Inc, H1 2018

Hepatocellular Carcinoma Pipeline by Amgen Inc, H1 2018

Hepatocellular Carcinoma Pipeline by AndroScience Corp, H1 2018

Hepatocellular Carcinoma Pipeline by ArQule Inc, H1 2018

Hepatocellular Carcinoma Pipeline by Array BioPharma Inc, H1 2018

Hepatocellular Carcinoma Pipeline by Aslan Pharmaceuticals Pte Ltd, H1 2018

Hepatocellular Carcinoma Pipeline by AstraZeneca Plc, H1 2018

Hepatocellular Carcinoma Pipeline by AVEO Pharmaceuticals Inc, H1 2018

Hepatocellular Carcinoma Pipeline by Bavarian Nordic A/S, H1 2018

Hepatocellular Carcinoma Pipeline by Bayer AG, H1 2018

Hepatocellular Carcinoma Pipeline by BeiGene Ltd, H1 2018

Hepatocellular Carcinoma Pipeline by Bio-Cancer Treatment International Ltd, H1 2018

Hepatocellular Carcinoma Pipeline by Biomics Biotechnologies Co Ltd, H1 2018

Hepatocellular Carcinoma Pipeline by Bioneer Corp, H1 2018

Hepatocellular Carcinoma Pipeline by Blueprint Medicines Corp, H1 2018

Hepatocellular Carcinoma Pipeline by Boehringer Ingelheim GmbH, H1 2018

Hepatocellular Carcinoma Pipeline by Boston Biomedical Inc, H1 2018

Hepatocellular Carcinoma Pipeline by Bristol-Myers Squibb Co, H1 2018

Hepatocellular Carcinoma Pipeline by Can-Fite BioPharma Ltd, H1 2018

Hepatocellular Carcinoma Pipeline by CARsgen Therapeutics Ltd, H1 2018

Hepatocellular Carcinoma Pipeline by CASI Pharmaceuticals Inc, H1 2018

Hepatocellular Carcinoma Pipeline by CBT Pharmaceuticals Inc, H1 2018

Hepatocellular Carcinoma Pipeline by CCRP Therapeutics GmbH, H1 2018

Hepatocellular Carcinoma Pipeline by Celgene Corp, H1 2018

Hepatocellular Carcinoma Pipeline by Cellular Biomedicine Group Inc, H1 2018

Hepatocellular Carcinoma Pipeline by Celsion Corp, H1 2018

Hepatocellular Carcinoma Pipeline by China Medical System Holdings Ltd, H1 2018

Hepatocellular Carcinoma Pipeline by Chipscreen Biosciences Ltd, H1 2018

Hepatocellular Carcinoma Pipeline by Chugai Pharmaceutical Co Ltd, H1 2018

Hepatocellular Carcinoma Pipeline by Conatus Pharmaceuticals Inc, H1 2018

Hepatocellular Carcinoma Pipeline by Curevac AG, H1 2018

Hepatocellular Carcinoma Pipeline by Delcath Systems Inc, H1 2018

Hepatocellular Carcinoma Pipeline by Double Bond Pharmaceutical International AB, H1 2018

Hepatocellular Carcinoma Pipeline by eFFECTOR Therapeutics Inc, H1 2018

Hepatocellular Carcinoma Pipeline by Eiger BioPharmaceuticals Inc, H1 2018

Hepatocellular Carcinoma Pipeline by Eisai Co Ltd, H1 2018

Hepatocellular Carcinoma Pipeline by Eli Lilly and Co, H1 2018

Hepatocellular Carcinoma Pipeline by Epeius Biotechnologies Corp, H1 2018

Hepatocellular Carcinoma Pipeline by Epizyme Inc, H1 2018

Hepatocellular Carcinoma Pipeline by Eureka Therapeutics Inc, H1 2018

Hepatocellular Carcinoma Pipeline by Exelixis Inc, H1 2018

Hepatocellular Carcinoma Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Hepatocellular Carcinoma Pipeline by Faron Pharmaceuticals Oy, H1 2018

Hepatocellular Carcinoma Pipeline by Galaxy Biotech LLC, H1 2018

Hepatocellular Carcinoma Pipeline by GC Pharma, H1 2018

Hepatocellular Carcinoma Pipeline by Genelux Corp, H1 2018

Hepatocellular Carcinoma Pipeline by Genentech Inc, H1 2018

Hepatocellular Carcinoma Pipeline by Genoscience Pharma, H1 2018

Hepatocellular Carcinoma Pipeline by Genosco Inc, H1 2018

Hepatocellular Carcinoma Pipeline by Gilead Sciences Inc, H1 2018

Hepatocellular Carcinoma Pipeline by GlaxoSmithKline Plc, H1 2018

Hepatocellular Carcinoma Pipeline by Golden Biotechnology Corp, H1 2018

Hepatocellular Carcinoma Pipeline by H3 Biomedicine Inc, H1 2018

Hepatocellular Carcinoma Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2018

Hepatocellular Carcinoma Pipeline by Horizon Pharma Plc, H1 2018

Hepatocellular Carcinoma Pipeline by Immatics Biotechnologies GmbH, H1 2018

Hepatocellular Carcinoma Pipeline by Immunicum AB, H1 2018

Hepatocellular Carcinoma Pipeline by Immunitor Inc, H1 2018

Hepatocellular Carcinoma Pipeline by Immunomedics Inc, H1 2018

List of Figures

List of Figures

Number of Products under Development for Hepatocellular Carcinoma, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Top 10 Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports